Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
Ascendis Pharma A/S (Nasdaq: ASND) has announced its plans to release second quarter 2024 financial results and provide a business update on Tuesday, September 3, 2024, after the U.S. financial markets close. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can access the live webcast or register for the teleconference in advance. The webcast link will also be available on the Investors & News section of the Ascendis Pharma website. A replay of the webcast will be accessible on the company's website for 30 days following the event.
Ascendis Pharma A/S (Nasdaq: ASND) ha annunciato i suoi piani per la pubblicazione dei risultati finanziari del secondo trimestre 2024 e per fornire un aggiornamento aziendale il martedì 3 settembre 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda ospiterà una teleconferenza e un webcast dal vivo alle 16:30 ora della costa orientale dello stesso giorno per discutere i risultati. Le parti interessate possono accedere al webcast dal vivo o registrarsi in anticipo per la teleconferenza. Il link al webcast sarà anche disponibile nella sezione Investitori & News del sito web di Ascendis Pharma. Una registrazione del webcast sarà accessibile sul sito dell'azienda per 30 giorni dopo l'evento.
Ascendis Pharma A/S (Nasdaq: ASND) ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 y proporcionar una actualización empresarial el martes 3 de septiembre de 2024, después del cierre de los mercados financieros de EE. UU. La compañía llevará a cabo una conferencia telefónica y transmisión web en vivo a las 4:30 p.m. hora del Este el mismo día para discutir los resultados. Las partes interesadas pueden acceder a la transmisión web en vivo o registrarse con anticipación para la teleconferencia. El enlace a la transmisión web también estará disponible en la sección de Inversores & Noticias del sitio web de Ascendis Pharma. Una repetición de la transmisión web estará disponible en el sitio web de la compañía durante 30 días siguientes al evento.
Ascendis Pharma A/S (Nasdaq: ASND)는 2024년 2분기 재무 결과를 발표하고 2024년 9월 3일 화요일에 미국 금융 시장이 마감된 후 사업 업데이트를 제공할 계획을 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 결과에 대해 논의하기 위해 컨퍼런스 콜 및 라이브 웨비나를 개최할 것입니다. 관심 있는 분들은 라이브 웨비나에 접속하거나 사전 등록하여 전화 회의에 참여할 수 있습니다. 웨비나 링크는 Ascendis Pharma 웹사이트의 투자자 및 뉴스 섹션에서도 확인할 수 있습니다. 이벤트 후 30일 동안 회사 웹사이트에서 웨비나 재생을 이용할 수 있습니다.
Ascendis Pharma A/S (Nasdaq: ASND) a annoncé ses plans pour publier les résultats financiers du deuxième trimestre 2024 et fournir une mise à jour commerciale le mardi 3 septembre 2024, après la fermeture des marchés financiers américains. La société organisera une conférence téléphonique et un webinaire en direct à 16h30 heure de l'Est le même jour pour discuter des résultats. Les parties intéressées peuvent accéder au webinaire en direct ou s'inscrire à l'avance pour la conférence téléphonique. Le lien vers le webinaire sera également disponible dans la section Investisseurs & Nouvelles du site web d'Ascendis Pharma. Un enregistrement du webinaire sera accessible sur le site de l'entreprise pendant 30 jours suivant l'événement.
Ascendis Pharma A/S (Nasdaq: ASND) hat angekündigt, die finanziellen Ergebnisse für das zweite Quartal 2024 zu veröffentlichen und am Dienstag, den 3. September 2024, nach dem Schließen der US-Finanzmärkte ein Unternehmensupdate bereitzustellen. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Live-Webcast veranstalten, um die Ergebnisse zu besprechen. Interessierte Parteien können auf den Live-Webcast zugreifen oder sich im Voraus für die Telefonkonferenz registrieren. Der Webcast-Link wird auch im Bereich Investoren & Nachrichten auf der Website von Ascendis Pharma verfügbar sein. Eine Wiederholung des Webcasts wird 30 Tage lang nach der Veranstaltung auf der Website des Unternehmens zugänglich sein.
- None.
- None.
COPENHAGEN, Denmark, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2024 financial results and provide a business update on Tuesday, September 3, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on September 3, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2024 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © August 2024 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Tim Lee | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| +1 (650) 374-6343 | +1 (650) 709-8875 |
| tle@ascendispharma.com | media@ascendispharma.com |
| ir@ascendispharma.com | |
| Patti Bank | |
| ICR Westwicke | |
| +1 (415) 513-1284 | |
| patti.bank@westwicke.com |
FAQ
When will Ascendis Pharma (ASND) report its Q2 2024 financial results?
What time is Ascendis Pharma's (ASND) Q2 2024 earnings call scheduled for?
How can investors access Ascendis Pharma's (ASND) Q2 2024 earnings webcast?
How long will the replay of Ascendis Pharma's (ASND) Q2 2024 earnings webcast be available?
